Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + Gemcitabine
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Ovarian Cancer
Conditions
Platinum-resistant Ovarian Cancer
Trial Timeline
Feb 7, 2025 → May 23, 2028
NCT ID
NCT06619236About Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + Gemcitabine
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + Gemcitabine is a phase 3 stage product being developed by Genmab for Platinum-resistant Ovarian Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06619236. Target conditions include Platinum-resistant Ovarian Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06619236 | Phase 3 | Active |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer